ProMIS Neurosciences Q2 net loss widens
ProMIS Neurosciences Q2 net loss widens
Overview
US biotechnology firm's Q2 net loss widened yr/yr
Cash and short-term investments rose to $53.4 mln, funding operations through 2027
Company reported positive blinded six-month interim safety and biomarker results from Phase 1b PRECISE-AD trial
Outlook
Company expects to report unblinded 12-month topline PRECISE-AD data in Q1 2027
Company says existing cash expected to fund operations through 2027
Result Drivers
CLINICAL TRIAL PROGRESS - Co cited positive blinded six-month interim safety and biomarker results from PRECISE-AD Phase 1b trial, including no ARIA-E cases and early declines in plasma pTau217 and CSF MTBR-tau243
INCREASED CASH POSITION - Cash and short-term investments rose to $53.4 mln, mainly due to $70.1 mln in net proceeds from a private placement in January 2026
Company press release: ID:nGNX7VsL2w
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Loss |
| $11.70 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for ProMIS Neurosciences Inc is $35.00, about 141.4% above its August 12 closing price of $14.50
Reuters Recommended Reads
Aug 12 - Acumen Pharmaceuticals Q2 net loss widens, misses analyst estimates
Aug 12 - Annexon Biosciences Q2 net loss widens, cash runway extended
Aug 10 - Metagenomi Q2 net loss widens cash runway seen through 2027
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)